Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 141,207	$ 174,960
Short-term marketable securities	757,745	657,371
Prepaid expenses and other current assets	35,754	32,105
Total current assets	934,706	864,436
Long-term marketable securities	78,463	359,373
Property and equipment, net	58,717	55,236
Finance lease right-of-use asset	50,363	47,533
Operating lease right-of-use asset	21,022	22,861
Other non-current assets	22,970	24,741
Total assets	1,166,241	1,374,180
Current liabilities:
Accounts payable	10,844	11,137
Accrued compensation	12,068	24,728
Accrued clinical and other research and development costs	23,379	22,822
Accrued manufacturing costs	9,028	12,779
Operating lease liability, current	8,871	8,308
Deferred research and development funding liability, current	19,861	14,129
Other accrued costs and current liabilities	7,006	8,305
Total current liabilities	91,057	102,208
Operating lease liability, less current portion	32,110	36,673
Finance lease liability, less current portion	5,577	5,615
Deferred research funding and development liability, less current portion	10,444	0
Total liabilities	139,188	144,496
Commitments and contingencies (Note 6)
Stockholders' equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024	0	0
Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 145,685,442 shares and 144,220,986 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	1,783	1,768
Additional paid-in capital	2,820,404	2,764,880
Accumulated other comprehensive income	939	2,020
Accumulated deficit	(1,796,073)	(1,538,984)
Total stockholders' equity	1,027,053	1,229,684
Total liabilities and stockholders’ equity	$ 1,166,241	$ 1,374,180